Literature DB >> 15771905

Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.

Chi-Ming Wu1, Reiping Tang, Jeng-Yi Wang, Chung-Rong Changchien, Ling-Ling Hsieh.   

Abstract

Mutations in codons 12 and 13 of the K-RAS oncogene are detected at a remarkably high frequency in colorectal adenocarcinoma and are believed to be a critical event in oncogenesis. In the present study, we evaluated colorectal tumor specimens from Taiwan for mutations in K-RAS codons 12 and 13 using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and direct DNA sequencing. Mutations were found in 48 of 181 (26.5%) tumors, 30 mutations were G-->A transitions (62.5% of all mutations), 14 were G-->T transversions (29.2%), and only 4 were G-->C transversions (8.3%). Similar relative mutation frequencies and spectra were found regardless of the sex of the patient, the tumor grade, or the tumor stage. The high frequency of transitions among K-RAS mutation suggests that G/T mismatches play an important role in the oncogenesis of colorectal adenocarcinoma, implying that alkylating carcinogens may be involved in the colorectal carcinogenesis. Although the frequency of mutation (26.5%) appears to be lower than those reported in the United States (40%), France (49%), and the Netherlands (34%), the spectrum of point mutations in codons 12 and 13 of the K-RAS gene in the Taiwan Chinese population appears to be similar. The reason for these results may be that diet and ethnicity are not rate limit factors in controlling the spectra of mutations but influence on the frequency of K-RAS mutations in human colorectal adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771905     DOI: 10.1016/j.cancergencyto.2004.08.030

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.

Authors:  Brooke E Sylvester; Dezheng Huo; Andrey Khramtsov; Jing Zhang; Rana V Smalling; Sope Olugbile; Blase N Polite; Olufunmilayo I Olopade
Journal:  Clin Cancer Res       Date:  2011-11-23       Impact factor: 12.531

2.  Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer.

Authors:  Lee Cheng Phua; Hui Wen Ng; Angie Hui Ling Yeo; Elya Chen; Michelle Shu Mei Lo; Peh Yean Cheah; Eric Chun Yong Chan; Poh Koon Koh; Han Kiat Ho
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

3.  Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.

Authors:  Jing Gao; Yan-Yan Li; Ping-Nai Sun; Lin Shen
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

4.  Coexistence of K-ras mutations and HPV infection in colon cancer.

Authors:  Nur Buyru; Ayda Tezol; Nejat Dalay
Journal:  BMC Cancer       Date:  2006-05-04       Impact factor: 4.430

5.  MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.

Authors:  E Nagy; K B Gajjar; I I Patel; S Taylor; P L Martin-Hirsch; H F Stringfellow; F L Martin; D H Phillips
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

6.  Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions.

Authors:  Huidan Zhang; Jin Song; Hui Ren; Zhangrun Xu; Xiaonan Wang; Lianfeng Shan; Jin Fang
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.